ProPhase Labs, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ProPhase Labs, Inc. (PRPH) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$3.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-19
- ProPhase Labs, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.05M.
- ProPhase Labs, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$5.17M, a 230.48% decline year-over-year.
- ProPhase Labs, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$4.47M.
- ProPhase Labs, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was $3.97M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month |
|---|---|---|---|
| 2026-06-30 | -$3.05M 10-Q · filed 2026-08-19 | -$8.23M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | -$5.17M 10-Q/A · filed 2026-07-09 | -$5.35M 10-Q · filed 2026-06-30 | |
| 2025-06-30 | -$4.47M 10-Q · filed 2026-08-19 | -$506.00K 10-Q · filed 2026-08-19 | |
| 2025-03-31 | $3.97M 10-Q/A · filed 2026-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |